Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2021-02-02
2021-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Overnight Upper Airway Infiltration in Spinal Cord Injury
NCT05391308
Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease
NCT03373643
Follow-up of Patients With Obstructive Sleep Apnea in Primary Care.
NCT01918449
Screening of Obstructive Sleep Apnea Syndrome in Residents of a Unit of Long-term Care Under Mixed Food
NCT02839499
Functional Magnetic Resonance Imaging in Patients With Obstructive Sleep Apnea Syndrome
NCT05147649
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective : Evaluation of changes in upper airway collapse in patients with central sleep apnea syndrome with preserved LVEF heart failure ("central SAS case"), compared with snoring subjects free from sleep apnea syndrome ("Simple snoring witnesses")
Secondary objectives :
* Study the collapsibility of VAS according to the type of apnea ("central SAS case" versus "obstructive SAS case").
* To study the association between the collapsibility of VAS and the global and central apnea-hypopnoea index (IAH).
* Study the association between the type of disorder ("central SAS case" versus "simple snoring controls", "central SAS case" versus "obstructive SAS controls") and cardiorespiratory coupling.
* Study the association between the type of disorder ("central SAS case" versus "simple snoring controls", "central SAS case" versus "obstructive SAS controls") and the CO2 response slope.
* Establish a map of the respiratory neural network in patients with central SAS with preserved ejection fraction.
* Study the association between the volumes in acoustic pharyngometry and the values of the Pcrit
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Central SAS cases
Patients with central apnea
Critical airway closure pressure (Pcrit) measurment
Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
Acoustic pharyngometry
Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
High density surface electroencephalogram neural mapping
Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
Obstructive SAS controls
Patients with moderate to severe obstructive apnea (apnea-hypopnoea index ≥ 15 / h)
Critical airway closure pressure (Pcrit) measurment
Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
Acoustic pharyngometry
Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
Snorers controls
Snorers controls : Patients with snoring, with or without mild obstructive apneas (index of apnea-hypopneas \<15 / h)
Critical airway closure pressure (Pcrit) measurment
Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
Acoustic pharyngometry
Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Critical airway closure pressure (Pcrit) measurment
Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
Acoustic pharyngometry
Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
High density surface electroencephalogram neural mapping
Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years and ≤85 years
* With preserved LVEF heart failure (defined as LVEF ≥ 45% on ultrasound, MRI or isotopic ventriculography)
* Central SAS Group: Central to severe sleep apnea syndrome, defined by an apnea-hypopnoea index (IAH) greater than 15 per hour, of which at least 30% are central events;
* Obstructive SAS group: Moderate to severe obstructive sleep apnea syndrome, defined by an apnea-hypopnoea index (IAH) greater than 15 per hour, with a central event proportion of less than 30%
* Group "snoring": absence of sleep apnea syndrome or mild sleep apnea syndrome (IAH \<15 / h) in polysomnography, and presence of snoring on at least 30% of the night of recording.
* Free, informed and written consent
* Patient affiliated to a social security scheme (beneficiary or beneficiary)
Exclusion Criteria
* Participation in a research protocol involving the human person in the previous months if an exclusion directive is given in this protocol
* Use of respiratory or sedative depressant drugs, systemic corticosteroid therapy
* Impaired systolic function (defined by LVEF \<45% in ultrasound, MRI or isotopic ventriculography)
* Unstable cardiovascular disease (cardiovascular event of less than one month)
* Recent surgery of the ENT sphere (less than 6 months)
* Central neurological pathology known
* Known, severe respiratory pathology (severity left to the investigator's discretion)
* Renal insufficiency (creatinine clearance \<60 mL / min) or severe hepatic impairment
* Primary or secondary hemostasis disorder
* Patient on anticoagulant (antivitamin K, direct oral anticoagulant, heparin and related). Antiplatelet agents are allowed.
* Psychiatric pathology according to DSM-V criteria, unbalanced
* Pulsed saturation with oxyhemoglobin \<88% at rest, on awakening
* Allergy to lidocaine
* Patient under tutorship or curatorship
* Failure to perform a prior medical examination
* Tympanic perforation
18 Years
85 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marie-Pia D'ORTHO, Professor
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Bichat-Claude Bernard
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP 180442
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.